- Relationship to Diabetes
- Type 1
- Pronouns
- He/Him
National Institute for Health and Care Excellence (NICE) is publishing draft guidance today, approving the use of tirzepatide (brand name Mounjaro) for treating type 2 diabetes in England and Wales.
Evidence from clinical trials showed using tirzepatide resulted in significant reductions in blood sugar levels and body weight compared with semaglutide, insulin therapy or a placebo. The evidence showed using tirzepatide resulted in 81% to 97% of people reaching better glucose control and 54% to 88% reaching a 5% or greater reduction in body weight, which were significantly more than any of the comparators.
Douglas Twenefour, Head of Care at Diabetes UK, said: “We welcome NICE’s decision to approve tirzepatide (Mounjaro) to be prescribed on the NHS as this will provide another effective treatment option for managing type 2 diabetes. It is very promising that the trial data showed great improvements in blood glucose management and weight loss.
“The current GLP-1 medication shortages are causing stress and uncertainty for many people with type 2 diabetes. Whilst the approval of tirzepatide is welcome, we are calling for more action to ensure ongoing and sufficient supply of these medications to people with type 2 diabetes.”
Final guidance is scheduled to be published on 11 October 2023. Once final guidance is published the product will be made available in the NHS within 90 days dependent on the supply of licensed product by the manufacturer.
Tirzepatide is injected weekly by the patient.
It is licensed to treat adults who are finding it difficult to manage their type 2 diabetes alongside diet and exercise when metformin (the main first line medicine for type 2 diabetes) cannot be tolerated. In its submission to NICE the company positioned it as an option for a narrower population - adults with type 2 diabetes who are not achieving recommended glucose outcomes with 3 or more antidiabetic drugs. This makes it an alternative to similar treatments such as dulaglutide, liraglutide and semaglutide (ozempic/rybelsus) which are already recommended for use in the NHS.
Evidence from clinical trials showed using tirzepatide resulted in significant reductions in blood sugar levels and body weight compared with semaglutide, insulin therapy or a placebo. The evidence showed using tirzepatide resulted in 81% to 97% of people reaching better glucose control and 54% to 88% reaching a 5% or greater reduction in body weight, which were significantly more than any of the comparators.
Douglas Twenefour, Head of Care at Diabetes UK, said: “We welcome NICE’s decision to approve tirzepatide (Mounjaro) to be prescribed on the NHS as this will provide another effective treatment option for managing type 2 diabetes. It is very promising that the trial data showed great improvements in blood glucose management and weight loss.
“The current GLP-1 medication shortages are causing stress and uncertainty for many people with type 2 diabetes. Whilst the approval of tirzepatide is welcome, we are calling for more action to ensure ongoing and sufficient supply of these medications to people with type 2 diabetes.”
Final guidance is scheduled to be published on 11 October 2023. Once final guidance is published the product will be made available in the NHS within 90 days dependent on the supply of licensed product by the manufacturer.
Tirzepatide is injected weekly by the patient.
It is licensed to treat adults who are finding it difficult to manage their type 2 diabetes alongside diet and exercise when metformin (the main first line medicine for type 2 diabetes) cannot be tolerated. In its submission to NICE the company positioned it as an option for a narrower population - adults with type 2 diabetes who are not achieving recommended glucose outcomes with 3 or more antidiabetic drugs. This makes it an alternative to similar treatments such as dulaglutide, liraglutide and semaglutide (ozempic/rybelsus) which are already recommended for use in the NHS.